NCT05221008

A Trial of SHR6508 in Secondary Hyperparathyroidism

Study on Tolerability, Pharmacokinetics and Pharmacodynamics of SHR6508 in Chinese Patients With Secondary Hyperparathyroidism of Chronic Kidney Disease Treated by Maintenance Hemodialysis

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 54 (actual)
• Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The study is being conducted to evaluate the tolerability, pharmacokinetics and pharmacodynamics of SHR6508 for Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis

Conditions

• Secondary Hyperparathyroidism

Interventions

Type	Name	Description
DRUG	SHR6508；Placebo	Group A:SHR6508 low dose
DRUG	SHR6508；Placebo	Group B:SHR6508 medium dose
DRUG	SHR6508；Placebo	Group C:SHR6508 high dose
DRUG	SHR6508；Placebo	Group D:SHR6508 high dose(single dose)

Timeline

• Start date: 2022-03-10
• Primary completion: 2023-07-07
• Completion: 2023-08-02
• First posted: 2022-02-02
• Last updated: 2023-08-08

Locations

1 site across 1 country: China